Galen Growth ceased operations on 31 October 2026.
HealthTech Alpha is no longer available. This archive keeps our published research freely available until 31 December 2026. Reports reflect the data at the time of publication and will not be updated.
Galen Growth research archive
This archive preserves Galen Growth's research on digital health investment, innovation, partnerships, clinical evidence, and market development.
2026 annual report
Sixth annual edition
The sixth annual Index benchmarks 24 pharmaceutical companies across digital health strategy and the strength of their recent partner portfolios.
Explore our intelligence
Published reports on funding, ecosystems, innovation, evidence, and market development.
02Editorial analysis of the events, companies, and strategic shifts shaping digital health.
03The annual evidence-led selection of promising early-stage digital health ventures.
04Static practical resources for market evaluation, diligence, and healthcare innovation.
Published insight
The merger of Redesign Health and ARC Global, alongside the proposed acquisition of AVIA, promises to transform hospitals from customers of innovation into its creators. But the bigger challenge may be knowing which companies deserve to exist.
Read the analysisResearch library
Presented by Galen Growth at Health Revolution Congress 2026 in Barcelona, this presentation explores how Health Management Solutions are becoming the operating layer of modern healthcare as AI adoption, investment and enterprise-scale deployment accelerate.
M&A now accounts for 95% of digital health exits as the IPO window stays shut to all but the most evidence-led ventures. Galen Growth's Digital Health Exits 2026 report — powered by HealthTech Alpha — analyses 282 exits from 2025 to June 2026 and the Roche/PathAI deal that turns vendor neutrality into a board-level governance question.